MAIA Biotechnology
MAIA | AMEX
$1.01
+$0.01 (+0.50%)
At close: Nov 16, 2026, 4:00 PM ET
$1.02
+$0.01 (+0.99%)
After-hours:
Nov 16, 2026, 7:20 PM ET
MAIA Biotechnology Company Profile
Company profile explainedCompany Profile
MAIA Biotechnology, Inc. is a clinical-stage biotech firm dedicated to discovering, developing, and commercializing treatments for various cancers, with a primary focus on non-small cell lung cancer. The company's leading experimental compound, THIO, is an investigational drug candidate that utilizes a unique dual mechanism by targeting telomeres and stimulating an immune response. Established in 2018, the enterprise maintains its headquarters in Chicago, Illinois.
Key Executives
| Name | Position |
|---|---|
| Vlad Vitoc | Co-Founder, President, Chief Executive Officer & Chairman of the Board of Directors |
| Jeffrey C. Himmelreich | Head of Finance and Principal Financial & Accounting Officer |
| Linda Moreira | Company Secretary |
| Sergei Gryaznov | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 07, 2026 | 424B3 | Filing |
| Oct 06, 2026 | EFFECT | Filing |
| Oct 06, 2026 | 8-K | Current Report |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 4 | Filing |
| Oct 02, 2026 | 424B3 | Filing |
| Oct 02, 2026 | 4 | Filing |
MAIA Biotechnology
| Country | United States |
| IPO Date | Jul 28, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 13 |
| CEO | Vlad Vitoc |
Contact Details
444 West Lake Street Chicago,
Illinois 60606 United States
Stock Details
| Ticker Symbol | MAIA |
| Exchange | AMEX |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001878313 |
| CUSIP Number | 552641102 |
| ISIN Number | US5526411021 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove MAIA